DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $272,000 | +7.9% | 828 | 0.0% | 0.01% | +11.1% |
| Q3 2021 | $252,000 | +21.7% | 828 | +7.4% | 0.01% | +28.6% |
| Q2 2021 | $207,000 | -7.2% | 771 | -25.4% | 0.01% | -36.4% |
| Q3 2020 | $223,000 | -47.9% | 1,034 | -79.4% | 0.01% | -38.9% |
| Q1 2017 | $428,000 | -14.2% | 5,009 | -21.8% | 0.02% | -18.2% |
| Q4 2016 | $499,000 | -70.6% | 6,409 | -70.4% | 0.02% | -75.3% |
| Q3 2016 | $1,699,000 | -38.5% | 21,670 | -20.7% | 0.09% | -43.3% |
| Q2 2016 | $2,761,000 | -8.0% | 27,335 | -13.6% | 0.16% | -47.0% |
| Q1 2016 | $3,000,000 | -59.3% | 31,630 | -60.1% | 0.30% | -51.6% |
| Q4 2015 | $7,365,000 | +17.2% | 79,300 | +7.5% | 0.61% | +11.3% |
| Q3 2015 | $6,285,000 | +38.1% | 73,760 | +38.8% | 0.55% | +51.1% |
| Q2 2015 | $4,550,000 | -30.7% | 53,155 | -31.3% | 0.36% | -33.5% |
| Q1 2015 | $6,566,000 | -10.2% | 77,340 | -9.3% | 0.55% | -8.8% |
| Q4 2014 | $7,308,000 | +2183.8% | 85,267 | +1954.6% | 0.60% | +1969.0% |
| Q4 2013 | $320,000 | – | 4,150 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |